TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

TRACON Pharmaceuticals (TCON) announced that Charles Theuer, M.D., Ph.D., will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting at 7:00 AM ET on May 23, 2022, on the company's website. TRACON focuses on developing targeted cancer therapies and partners with life science companies through a unique product development platform. Their pipeline includes Envafolimab, YH001, TRC102, and TJ004309, aimed at various cancer treatments.

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Tuesday, May 23, 2022, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue share partnership, or through franchising TRACON’s product development platform by licensing TRACON’s clinical know-how. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:	Investor Contact:
Mark Wiggins	Brian Ritchie
Chief Business Officer	LifeSci Advisors LLC
(858) 251-3492	(212) 915-2578
mwiggins@traconpharma.com	britchie@lifesciadvisors.com

 

FAQ

What event will TRACON Pharmaceuticals participate in on May 23-26, 2022?

TRACON Pharmaceuticals will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.

Where can I watch the TRACON Pharmaceuticals presentation?

The TRACON Pharmaceuticals presentation will be available on-demand on their website starting May 23, 2022, at 7:00 AM ET.

What is the focus of TRACON Pharmaceuticals?

TRACON Pharmaceuticals focuses on developing targeted cancer therapeutics and utilizes a cost-efficient, CRO-independent product development platform.

What are some of the drugs in TRACON Pharmaceuticals' pipeline?

TRACON Pharmaceuticals' pipeline includes Envafolimab for sarcoma, YH001 for CTLA-4, TRC102 for lung cancer, and TJ004309 for advanced solid tumors.

How does TRACON Pharmaceuticals partner with other companies?

TRACON Pharmaceuticals partners through profit-sharing, revenue-sharing, or franchising their product development platform to other life science companies.